Literature DB >> 12432268

Cycling to cancer with cyclin D1.

J Alan Diehl1.   

Abstract

Genetic aberrations in the regulatory circuits that govern transit through the G(1) phase of the cell cycle occur frequently in human cancer and overexpression of the G(1) phase cyclin, cyclin D1, is one of the most commonly observed alterations. Cyclin D1 accumulates and activates its cognate CDK (CDK4/6) in response to mitogenic growth factors in early to mid G(1) phase. The resulting cyclin D1-dependent kinase initiates the phosphorylation-dependent inactivation of the retinoblastoma tumor suppressor protein. Mitogen-dependent activation of the cyclin D1 kinase occurs through increased transcription, protein accumulation, cyclin/CDK assembly, reduced cyclin proteolysis, and decreased nuclear export. Perturbations at any step, which result in reduced growth factor requirements for cyclin D1/CDK activation, will provide cells with a distinct growth advantage over their normal counterparts and thus likely represents an early event in neoplasia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432268     DOI: 10.4161/cbt.72

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  169 in total

1.  RhoE inhibits cell cycle progression and Ras-induced transformation.

Authors:  Priam Villalonga; Rosa M Guasch; Kirsi Riento; Anne J Ridley
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

2.  Uncovering the role of genomic "dark matter" in human disease.

Authors:  Lance Martin; Howard Y Chang
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

Review 3.  Large non-coding RNAs: missing links in cancer?

Authors:  Maite Huarte; John L Rinn
Journal:  Hum Mol Genet       Date:  2010-08-20       Impact factor: 6.150

4.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

5.  Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

Authors:  Xiaofang Xu; Yuping Zhu
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

6.  Effects of Wnt-1 blockade in DEN-induced hepatocellular adenomas of mice.

Authors:  Argyrios Sklavos; Theofilos Poutahidis; Alexander Giakoustidis; Kali Makedou; Katerina Angelopoulou; Alexander Hardas; Paola Andreani; Argyro Zacharioudaki; George Saridis; Thomas Goulopoulos; Kalliopi Tsarea; Maria Karamperi; Vassilios Papadopoulos; Vassilios Papanikolaou; Apostolos Papalois; Stavros Iliadis; Satvinder Mudan; Daniel Azoulay; Dimitrios Giakoustidis
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

Review 7.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

8.  The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line.

Authors:  Jun-Ming Chen; Jue Zhang; Yong-Mei Xia; Xiao-Xia Wang; Jian Li
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

9.  Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.

Authors:  Wen-Bin Ou; Nan Ni; Rui Zuo; Weihao Zhuang; Meijun Zhu; Anastasios Kyriazoglou; Duolin Wu; Grant Eilers; George D Demetri; Haibo Qiu; Bin Li; Adrian Marino-Enriquez; Jonathan A Fletcher
Journal:  Oncogene       Date:  2019-08-01       Impact factor: 9.867

Review 10.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.